15
Registered trials
6
Recruiting
13
Unique sponsors
23
Unique IMPs
15
Commercial trials
Drug classes (ATC)
—
ATC code not specified
12
L
Oncology (ATC L)
2
V
Various (ATC V)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
11 substances
Kinase inhibitor
3 substances
Platinum compound
2 substances
Monoclonal antibody (immune)
1 substance
Monoclonal antibody (tumor, humanized)
1 substance
RAF/BRAF inhibitor
1 substance
Monoclonal antibody (immune, humanized)
1 substance
Monoclonal antibody (chimeric)
1 substance
Monoclonal antibody (primate)
1 substance
Antimetabolite
1 substance
Phase II/III:
1
Phase II:
2
Phase I/II:
2
Phase I:
9
Phase I (Other):
1
Phase II/III
1 trial-
RecruitingTaiho Oncology Inc. CommercialFUTIBATINIB
Phase II
2 trials-
RecruitingMerck Sharp & Dohme LLC CommercialMK-1084
-
EndedSichuan Kelun-Biotech Biopharmaceutical Co. Ltd. CommercialSKB264
Phase I/II
2 trials-
RecruitingPentixapharm AG CommercialGALLIUM (68GA), PENTIXAFOR; L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; PENTIXATHER, YTTRIUM-90
-
PendingRevolution Medicines Inc. Commercial(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE; (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; IVONESCIMAB; PEMETREXED; RMC-6291
Phase I
9 trials-
EndedAstraZeneca AB CommercialIMP not specified
-
EndedAstraZeneca AB CommercialIMP not specified
-
EndedChugai Pharmaceutical Co. Ltd. CommercialIMP not specified
-
EndedDaiichi Sankyo Inc. CommercialIMP not specified
-
RecruitingGenmab A/S CommercialIMP not specified
-
RecruitingGilead Sciences Inc. CommercialIMP not specified
-
EndedIncyte Corp. CommercialIMP not specified
-
EndedMerck Sharp & Dohme LLC CommercialIMP not specified
-
RecruitingRegeneron Pharmaceuticals Inc. CommercialIMP not specified
Phase I (Other)
1 trial-
EndedNovartis Pharma AG Commercial3-[6-(1-BENZYLPIPERIDIN-4-YL)-3-OXO-1H-ISOINDOL-2-YL]PIPERIDINE-2,6-DIONE; CAPMATINIB; HETERODIMERIC INTERLEUKIN-15; IERAMILIMAB; LACNOTUZUMAB; NAPORAFENIB; SPARTALIZUMAB; TAMINADENANT; TRAMETINIB DIMETHYL SULFOXIDE
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| AstraZeneca AB | Commercial | 2 | Phase I | 0 |
| Merck Sharp & Dohme LLC | Commercial | 2 | Phase I, Phase II | 1 |
| Chugai Pharmaceutical Co. Ltd. | Commercial | 1 | Phase I | 0 |
| Daiichi Sankyo Inc. | Commercial | 1 | Phase I | 0 |
| Genmab A/S | Commercial | 1 | Phase I | 1 |
| Gilead Sciences Inc. | Commercial | 1 | Phase I | 1 |
| Incyte Corp. | Commercial | 1 | Phase I | 0 |
| Regeneron Pharmaceuticals Inc. | Commercial | 1 | Phase I | 1 |
| Taiho Oncology Inc. | Commercial | 1 | Phase II/III | 1 |
| Novartis Pharma AG | Commercial | 1 | Phase I (Other) | 0 |
| Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. | Commercial | 1 | Phase II | 0 |
| Pentixapharm AG | Commercial | 1 | Phase I/II | 1 |
| Revolution Medicines Inc. | Commercial | 1 | Phase I/II | 0 |
New trials by year
2019
2
2023
3
2024
2
2025
3
2026
1